Latest Breaking News On - Genesiscare murdoch - Page 1 : comparemela.com

MELBOURNE, Australia, July 19, 2023 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces that the first patient has been dosed in a Phase I study of the Company's investigational targeted radiation therapy, TLX250, in combination with a Merck KGaA, Darmstadt, Germany (Merck) DNA-dependent protein kinase (DNA-PK) inhibitor candidate, peposertib (M3814). The study is being conducted in patients with solid tumours expressing carbonic-anhydrase IX (CAIX), a potential pan-cancer target. STARSTRUCK (ClinicalTrials.gov Identifier: NCT05868174) is a Phase Ib, open label, single-arm, multicentre dose escalation and dose expansion study to evaluate the safety profile, dosing and activity of TLX250 (177Lu-DOTA-girentuximab) in combination with the DNA damage response inhibitor (DDRi) peposertib, which is an inhibitor of DNA-PK. The target population is patients with CAIX-expressing solid tumours that are relapsed or refractory to standard therapies. Up to

United statesUnited kingdomMerck ddriNat lenzoKyahn williamsonColin haywardGenesiscare murdochHealth canadaTelix pharmaceuticalsMerck kgaEuropean unionMerck kgaaAustralian therapeutic goods administrationPrnewswire telix pharmaceuticals limitedGenesiscare group clinicalDrug administration